153 related articles for article (PubMed ID: 35072848)
1. The effects of metformin, pioglitazone, exenatide and exercise on fatty liver in obese diabetic rats: the role of IRS-1 and SOCS-3 molecules.
Lule KO; Akarsu E; Sayiner ZA; Lule NO; Balci SO; Demirel C; Bozdag Z; Korkmaz M; Yilmaz I
Inflammopharmacology; 2022 Feb; 30(1):243-250. PubMed ID: 35072848
[TBL] [Abstract][Full Text] [Related]
2. Effects of antidiabetics and exercise therapy on suppressors of cytokine signaling-1, suppressors of cytokine signaling-3, and insulin receptor substrate-1 molecules in diabetes and obesity.
Akarsu E; Sayiner ZA; Balcı SO; Demirel C; Bozdag Z; Korkmaz M; Yılmaz I
Rev Assoc Med Bras (1992); 2023; 69(1):112-118. PubMed ID: 36629649
[TBL] [Abstract][Full Text] [Related]
3. Exenatide ameliorates experimental non-alcoholic fatty liver in rats via suppression of toll-like receptor 4/NFκB signaling: Comparison to metformin.
Saad ZA; Khodeer DM; Zaitone SA; Ahmed AAM; Moustafa YM
Life Sci; 2020 Jul; 253():117725. PubMed ID: 32348835
[TBL] [Abstract][Full Text] [Related]
4. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
Blazina I; Selph S
Syst Rev; 2019 Nov; 8(1):295. PubMed ID: 31783920
[TBL] [Abstract][Full Text] [Related]
5. Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance.
Saad MJ; Araki E; Miralpeix M; Rothenberg PL; White MF; Kahn CR
J Clin Invest; 1992 Nov; 90(5):1839-49. PubMed ID: 1331176
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats.
Ding SY; Shen ZF; Chen YT; Sun SJ; Liu Q; Xie MZ
Acta Pharmacol Sin; 2005 May; 26(5):575-80. PubMed ID: 15842776
[TBL] [Abstract][Full Text] [Related]
7. Tangganjian decoction ameliorates type 2 diabetes mellitus and nonalcoholic fatty liver disease in rats by activating the IRS/PI3K/AKT signaling pathway.
Fan Y; He Z; Wang W; Li J; Hu A; Li L; Yan L; Li Z; Yin Q
Biomed Pharmacother; 2018 Oct; 106():733-737. PubMed ID: 29990865
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT).
Lavynenko O; Abdul-Ghani M; Alatrach M; Puckett C; Adams J; Abdelgani S; Alkhouri N; Triplitt C; Clarke GD; Vasquez JA; Li J; Cersosimo E; Gastaldelli A; DeFronzo RA
Diabetes Obes Metab; 2022 May; 24(5):899-907. PubMed ID: 35014145
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of swimming exercises and metformin on cardiac and aortic damage caused by a high-fat diet in obese rats with type 2 diabetes, by regulating the Bcl2/Bax signaling pathway.
Özüdoğru E; Atay E; Savran M; Aşci H; Özmen Ö; Topsakal Ş
Turk J Med Sci; 2023; 53(6):1582-1592. PubMed ID: 38813486
[TBL] [Abstract][Full Text] [Related]
10. Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.
Gastaldelli A; Repetto E; Guja C; Hardy E; Han J; Jabbour SA; Ferrannini E
Diabetes Obes Metab; 2020 Mar; 22(3):393-403. PubMed ID: 31692226
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone versus metformin in two rat models of glucose intolerance and diabetes.
Gad MZ; Ehssan NA; Ghiet MH; Wahman LF
Pak J Pharm Sci; 2010 Jul; 23(3):305-12. PubMed ID: 20566445
[TBL] [Abstract][Full Text] [Related]
12. Short-term combined treatment with exenatide and metformin is superior to glimepiride combined metformin in improvement of serum testosterone levels in type 2 diabetic patients with obesity.
Shao N; Yu XY; Yu YM; Li BW; Pan J; Wu WH; Zhang HJ; Ma XF; Hao M; Kuang HY
Andrologia; 2018 Sep; 50(7):e13039. PubMed ID: 29740874
[TBL] [Abstract][Full Text] [Related]
13. Metformin, pioglitazone, dapagliflozin and their combinations ameliorate manifestations associated with NAFLD in rats via anti-inflammatory, anti-fibrotic, anti-oxidant and anti-apoptotic mechanisms.
Shaaban HH; Alzaim I; El-Mallah A; Aly RG; El-Yazbi AF; Wahid A
Life Sci; 2022 Nov; 308():120956. PubMed ID: 36103959
[TBL] [Abstract][Full Text] [Related]
14. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review.
Zachou M; Flevari P; Nasiri-Ansari N; Varytimiadis C; Kalaitzakis E; Kassi E; Androutsakos T
Eur J Clin Pharmacol; 2024 Jan; 80(1):127-150. PubMed ID: 37938366
[TBL] [Abstract][Full Text] [Related]
15. Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver.
Xing LJ; Zhang L; Liu T; Hua YQ; Zheng PY; Ji G
Eur J Pharmacol; 2011 Oct; 668(3):467-71. PubMed ID: 21839075
[TBL] [Abstract][Full Text] [Related]
16. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse.
Kerouz NJ; Hörsch D; Pons S; Kahn CR
J Clin Invest; 1997 Dec; 100(12):3164-72. PubMed ID: 9399964
[TBL] [Abstract][Full Text] [Related]
17. Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis.
Kalavalapalli S; Bril F; Guingab J; Vergara A; Garrett TJ; Sunny NE; Cusi K
J Endocrinol; 2019 Jun; 241(3):293-305. PubMed ID: 31082799
[TBL] [Abstract][Full Text] [Related]
18. [Metformin prevents non-alcoholic fatty liver disease in rats: role of phospholipase A2/lysophosphatidylcholine lipoapoptosis pathway in hepatocytes].
Huang Y; Fu JF; Shi HB; Liu LR
Zhonghua Er Ke Za Zhi; 2011 Feb; 49(2):139-45. PubMed ID: 21426695
[TBL] [Abstract][Full Text] [Related]
19. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
Hookman P; Barkin JS
Am J Gastroenterol; 2003 Sep; 98(9):2093-7. PubMed ID: 14499793
[TBL] [Abstract][Full Text] [Related]
20. Stevioside Attenuates Insulin Resistance in Skeletal Muscle by Facilitating IR/IRS-1/Akt/GLUT 4 Signaling Pathways: An In Vivo and In Silico Approach.
Deenadayalan A; Subramanian V; Paramasivan V; Veeraraghavan VP; Rengasamy G; Coiambatore Sadagopan J; Rajagopal P; Jayaraman S
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
